Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Aged over 19 years~* Signed informed consent~* At visit 1, LDL-C ≤ 250mg/dL and Triglyceride \< 400 mg/dL~* After 4 weeks more TLC, At visit2, LDL-C ≤ 250mg/dL, Triglyceride \< 400 mg/dL and satisfied criteria according to Risk of cardiovascular disease~Exclusion Criteria:~* Current or past history of hypersensitivity to HMG-CoA reductase inhibitors and component of Ezetimibe~* Has an active liver disease and severe liver disorder (continous elevation of AST, ALT level or exceeds more than 3 times of normal upper limit)~* Has a severe renal failure and kidney injury (Creatinine level exceeds more than 2 times of normal upper limit)~* CK level exceeds more than 5 times of normal upper limit~* Uncontrolled hypertension patient (SBP≥ 180 mmHg or DBP ≥ 110 mmHg)~* Uncontrolled diabetes mellitus patient (HbA1c ≥ 9%)~* Uncontrolled malfunctional thyroidism (or at pre-visit 2, TSH level exceeds more than 1.5 times of normal upper limit)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HGP0816 5mg (Type: ACTIVE_COMPARATOR): None
- HGP0816 10mg (Type: ACTIVE_COMPARATOR): None
- HGP0816 20mg (Type: ACTIVE_COMPARATOR): None
- HCP1306 5/10mg (Type: EXPERIMENTAL): None
- HCP1306 10/10mg (Type: EXPERIMENTAL): None
- HCP1306 20/10mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).